Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

NCT05671822 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: SHR-A1811 and SHR-1701
DRUG: SHR-A1811 and capecitabine
DRUG: SHR-A181, SHR-1701, and capecitabine
DRUG: SHR-A1811, SHR-1316, and capecitabine
DRUG: SHR-A1811, SHR-1316, capecitabine,and oxaliplatin
DRUG: SHR-A1811, SHR-1316, and 5-FU
DRUG: SHR-A1811, SHR-1316, and capecitabine
DRUG: SHR-1316 and SHR-A1811
DRUG: SHR-A1811 and capecitabine
DRUG: SHR-A1811, SHR-1316, and 5-FU
DRUG: SHR-A1811and 5-FU
DRUG: SHR-A1811, SHR-1316, capecitabine,and oxaliplatin

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.